A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β-thalassemia.
Gene Therapy Demonstrates High Efficacy in Severe β-Thalassemia
Posted in biotech/medical
Posted in biotech/medical
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β-thalassemia.